As well as the high rate of KRAS activating mutations, sequence analysis has shown that PDACs demonstrate a mixture of tumor suppressor gene mutations, with TP53 being mutated or inactivated in 75% of PDAC and mutant TP53 being shown to drive pancreatic cancer (48). The gene discussed is KRAS; the disease is pancreatic neoplasm.